Clinical trials: Semaglutide
Overweight, Obesity
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine.
- Trial name
- STEP 5 (NCT03693430)
- Testing
- Semaglutide
- Where
- 41 sites in United States, Canada and 3 more
- Volunteers
- 304 people
- Sponsor
- Novo Nordisk A/S
Polycystic Ovarian Syndrome in Adolescent Females, Obesity (Disorder)
Effects of Glucagon-like Peptide-1 (GLP-1) Agonist in Neuro-reproductive Function in Obese Adolescent Females With Polycystic Ovary Syndrome (PCOS)
The prevalence of childhood obesity in the United States has more than tripled in the past four decades affecting one in every five adolescent girls and is disproportionally higher among racial and/or ethnic minorities.
- Trial name
- NCT07169136
- Testing
- GLP-1 Receptor Agonists
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nemours Children's Clinic
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Obese
Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome
Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss…
- Trial name
- RESTORE (NCT05819853)
- Testing
- Semaglutide Injectable Product (Wegovy and/or Ozempic)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
The purpose of this clinical study is to look into how well a study medicine called CagriSema helps children and adolescents living with diabetes lower their blood sugar and body weight.
- Trial name
- REIMAGINEYOUNG (NCT07282613)
- Testing
- CagriSema (Cagrilintide B and Semaglutide I)
- Where
- 58 sites in United States, Argentina and 8 more
- Volunteers
- 80 people
- Sponsor
- Novo Nordisk A/S
Obesity and Overweight
A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese
The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts.
- Trial name
- NCT03707990
- Testing
- NNC0165-1875, Semaglutide
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Pregnancy, Obesity
A Study to Evaluate the Safety of Exposure to Wegovy During Pregnancy
This is an observational cohort study using administrative insurance claims data. The aim of this non-interventional study (NIS) is to compare maternal, fetal and infant outcomes of women exposed to Wegovy during pregnancy to a…
- Conditions
- Pregnancy, Obesity, Overweight
- Trial name
- NCT05503927
- Testing
- No Intervention
- Where
- 2 sites in United States
- Volunteers
- 2,701 people
- Sponsor
- Novo Nordisk A/S
Craniopharyngioma, Child
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
Craniopharyngioma (CP) is a rare embryonic brain tumor of the sellar and parasellar region. Despite its benign histologic characteristics, it is locally aggressive and may cause severe morbidity from invasion into adjacent…
- Trial name
- SEMAFORCRANIO (NCT07845994)
- Testing
- Semaglutide (Wegovy) weekly injection
- Where
- 17 sites in France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Angers
Obesity
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects…
- Trial name
- NCT05064735
- Testing
- semaglutide 2.4 mg
- Where
- 122 sites in United States, Canada and 9 more
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Non-alcoholic Steatohepatitis
Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
- Trial name
- NCT05016882
- Testing
- NNC0194 0499 50 mg/mL, Semaglutide 3 mg/mL, NNC0174 0833 10 mg/mL
- Where
- 255 sites in United States, Australia and 22 more
- Volunteers
- 698 people
- Sponsor
- Novo Nordisk A/S
Pediatric Obesity, Metabolic and Bariatric Surgery
Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery).
- Conditions
- Pediatric Obesity, Metabolic and Bariatric Surgery, Semaglutide
- Trial name
- NCT06934655
- Testing
- Semaglutide 2.4 mg
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Children's Hospital Los Angeles
Obesity (Disorder)
JOULE - Metabolic Adaptation to Weight Loss in Response to a Behavioural Lifestyle Program With or Without Semaglutide in Adolescents With Obesity
The Joule MARS study is a single center, randomized, open label clinical trial aiming to explore the metabolic adaptations that occur in response to weight management in adolescents with obesity.
- Trial name
- JOULE-MARS (NCT06852391)
- Testing
- Semaglutide Pen Injector, Behavioural Lifestyle Program (BLP)
- Where
- Canada
- Volunteers
- 74 people
- Sponsor
- McMaster University
Obesity, Overweight
FutureShape Family
The number of adults and children living with obesity is increasing worldwide. Once childhood obesity has developed, more than 80% of children carry the obesity into adulthood, with a high risk of cardiometabolic disease, poor…
- Trial name
- NCT07872904
- Testing
- Family Care, Standard Care, Semaglutide (administered by PDS290 pen-injector)
- Where
- Denmark
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Signe Torekov
Obesity/Therapy
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults.
- Trial name
- PLASTIC (NCT07021937)
- Testing
- Semaglutide 1.7mg subcutaneous
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Colorado, Denver
Diabetes Mellitus, Type 2
A Research Study to Compare a New Medicine Oral Semaglutide to a Dummy Medicine in Children and Teenagers With Type 2 Diabetes
This study compares 2 medicines for type 2 diabetes: semaglutide (new medicine) and a dummy medicine (placebo). Semaglutide will be tested to see how well it works compared to the dummy medicine.
- Trial name
- PIONEER TEENS (NCT04596631)
- Testing
- Oral semaglutide
- Where
- 97 sites in United States, Australia and 20 more
- Volunteers
- 132 people
- Sponsor
- Novo Nordisk A/S
Obesity, Adolescent Obesity
Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents
The study plans to learn more about what happens to the body after bariatric surgery in people 12 to 24 years old. The study aims to understand why people respond differently to bariatric surgery and how to define success beyond…
- Conditions
- Obesity, Adolescent Obesity, Body-Weight Trajectory, Weight Loss Trajectory
- Trial name
- PRESSURE (NCT06575738)
- Testing
- Injectable semaglutide or injectable tirzepatide, Standard postoperative care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Colorado, Denver
Overweight, Obesity
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy"…
- Trial name
- NCT04102189
- Testing
- Semaglutide
- Where
- 51 sites in United States, Austria and 6 more
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Stage 1 Diabetes Mellitus, Type 1
GLP-1 RA for Stage 1 Type 1 Diabetes
This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes.
- Trial name
- NCT07430332
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Monogenic Obesity
A Multicenter Pharmacoepidemiological Cohort on Real Life Use of Semaglutide in Adolescents or Adults With Monogenic Obesity
Rare genetic forms of obesity, so called monogenic obesity are linked to alteration in energy balance involving hypothalamic pathways.
- Trial name
- ObGeSema (NCT06380426)
- Where
- 2 sites in France
- Volunteers
- 175 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 1 Diabetes
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
The goal of this study is to determine how a drug class called glucagon-like peptide-1 receptor agonists (GLP-1Ra) affects people during an early stage of Type 1 Diabetes undergoing clinical teplizumab treatment.
- Trial name
- GLP-TEP (NCT06338553)
- Testing
- Semaglutide (Rybelsus®)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt University Medical Center
Diabetes Mellitus, Type 2
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®
The purpose of this study is to assess the safety of long-term treatment with Ozempic® in patients with type 2 diabetes mellitus. People will get Ozempic® as prescribed by their doctor. People will be in this study about 3 years.
- Trial name
- NCT04469855
- Testing
- semaglutide
- Where
- 414 sites in Japan
- Volunteers
- 3,217 people
- Sponsor
- Novo Nordisk A/S